SEC Form 4 · accession 0001209191-18-057190
SURMODICS INC · SRDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gary R Maharaj
Officer — President & CEO · Director
Period of report
Nov 1, 2018
Accepted (ET)
Nov 5, 2018 · 4:38 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000924717
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Nov 1, 2018 | S | 4,193 | $62.1251 | D | 166,086 | D | |
| Common StockF3 | Nov 1, 2018 | S | 807 | $62.6427 | D | 165,279 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2018.
- F2Reflects the weighted average price of 4,193 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on November 1, 2018 with sale prices ranging from $61.50 to $62.43 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3Reflects the weighted average price of 807 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on November 1, 2018 with sale prices ranging from $62.51 to $63.085 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.